Delivery Order SPE2DB25D3108-SPE2DB25FPDZM
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Ibrance 100 mg tablets (7-count packages) with a ceiling value of $8,122.48. This is a firm fixed-price delivery order with an ultimate completion date of September 24, 2025, and was competitively awarded with no set-aside designation. The contract is performed from AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, supporting the federal government's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Ibrance 125 mg tablets in a quantity of seven units, with a ceiling value of $8,118.08. This firm fixed-price delivery order, which is expected to be completed by September 10, 2025, carries no set-aside designation and represents a competitively awarded transaction. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Ibrance 100 mg tablets (quantity 7s) with a ceiling value of $8,122.48. This firm fixed-price delivery order, with a completion date of September 30, 2025, represents a non-set-aside competitive award to support federal pharmaceutical procurement needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Ibrance 100 mg tablets (7-count), valued at $8,122.48 under a firm fixed price contract. This non-set-aside delivery order is scheduled for completion by September 3, 2025, with performance of work occurring at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical vendor for...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Ibrance 75 mg tablets in a quantity of seven units, with a ceiling value of $32,495.84. This is a firm fixed price delivery order with no set-aside designation, utilizing competitive procurement procedures. The order is scheduled for ultimate completion on October 8, 2025, with performance taking place at the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Ibrance 100 mg tablets in quantities of seven units. This firm fixed price delivery order, valued at $32,489.92, represents a competitive award with no set-aside designation and is scheduled for completion by September 24, 2025. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Ibrance 125 mg tablets (7-count) under a firm fixed-price contract with a ceiling value of $8,118.08 and an ultimate completion date of September 8, 2025. This non-set-aside award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $8,122.48 on August 12, 2025, for the supply of Ibrance 100 mg tablets (7-unit package). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 3, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency awarded a $8,123.96 delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Ibrance 75 mg tablets (quantity 7 units). This competitive, non-set-aside contract carries a firm fixed price and is scheduled for completion by September 5, 2025. The work will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $16,244.96 to AmerisourceBergen Drug Corp for the supply of Ibrance 100 mg tablets (7-count packaging) on September 9, 2025, with a completion date of September 30, 2025. This firm fixed-price delivery order represents a non-competitive set-aside arrangement and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare...
- SPE2DB25D3108Indefinite Delivery Contract
- SPE2DB25D3108-SPE2DB25FPDZMDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Ibrance 100 mg tablets (7-count packaging) with a ceiling value of $8,122.48. This firm fixed-price delivery order, with an ultimate completion date of October 9, 2025, represents a child contract under AmerisourceBergen's broader pharmaceutical supply relationship with DLA. The award was made through open competition with no set-aside designation, and fulfillment will occur at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order draws from AmerisourceBergen Drug Corp's significant Indefinite Delivery Contract with DLA Troop Support Medical (valued at $999,999,999.00 through December 2026), which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. Ibrance, a brand-name oncology medication, aligns with AmerisourceBergen's extensive portfolio of pharmaceutical products supplied to federal medical procurement needs across multiple therapeutic domains. As a major pharmaceutical distributor and critical vendor for military and veteran healthcare systems, AmerisourceBergen regularly fulfills federal medical supply requirements through DLA's Medical Supply Chain, supporting the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.1k | 9/18/25 |